



# GLAND PHARMA LIMITED

July 12, 2023

BSE Limited  
Surveillance Department  
Phiroze Jeejeebhoy Towers  
25th floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245  
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

**Sub: Clarification/Confirmation on news item appearing in [www.cnbctv18.com](http://www.cnbctv18.com)**

**Ref. No.:** L/SURV/ONL/RV/VK/ (2023-2024)/ 18

This is in reference to your e-mail dated 10<sup>th</sup> July 2023 seeking clarification on news item appearing in [www.cnbctv18.com](http://www.cnbctv18.com).

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI (LODR) Regulations, 2015), the Company promptly intimates to the Stock Exchanges of all events and information that may have a probable bearing on the operation / performance of the Company including all price sensitive information, as and when required from time to time.

The news items appeared in the Media is correct as the Company had received approval for ANDA for Fomepizole. However, it was not falling under the criteria of the materiality to be disclosed to the stock exchanges, as the expected annual revenue is less than the materiality threshold and hence it is not categorised as UPSI. The news article has no material impact on the operations of the Company. The product approval information is also available on the USFDA website.

Please take the same on record.

Yours truly,  
**For Gland Pharma Limited**

**P Sampath Kumar**  
**Company Secretary and Compliance Officer**